# Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

> **NCT07311577** · PHASE2 · RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Ovarian Cancer Metastatic
- Ovarian Cancer Metastatic Recurrent

## Interventions

- **DRUG:** RC48+Carboplatin+Bevacizumab

## Key facts

- **NCT ID:** NCT07311577
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311577, "Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07311577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*